Whitehawk Therapeutics (WHWK) Cash from Investing Activities (2016 - 2026)

Whitehawk Therapeutics (WHWK) has 11 years of Cash from Investing Activities data on file, last reported at $19.4 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $19.4 million, down 83.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$84.2 million (down 164.68% YoY), and the FY2025 annual result was $11.9 million, down 52.82% from the prior year.
• Cash from Investing Activities rose to $19.4 million in Q1 2026 per WHWK's latest filing, from $16.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $115.5 million in Q1 2025 and troughed at -$91.6 million in Q3 2025.
• A 5-year average of $402529.4 and a median of $5.1 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 183332.61% in 2022, then jumped 71095.65% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$84.4 million in 2022, then surged by 104.32% to $3.6 million in 2023, then jumped by 259.91% to $13.1 million in 2024, then climbed by 28.27% to $16.8 million in 2025, then grew by 15.34% to $19.4 million in 2026.
• Business Quant data shows WHWK's Cash from Investing Activities at $19.4 million in Q1 2026, $16.8 million in Q4 2025, and -$91.6 million in Q3 2025.